Abstract The 2013–2016 West Africa EBOV epidemic was the biggest EBOV outbreak to
date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of …

The recent Ebola epidemic exemplified the importance of understanding and controlling
emerging infections. Despite the importance of T cells in clearing virus during acute …

Ebola virus (EBOV) is known to cause a severe hemorrhagic fever resulting in high mortality.
Although the precise host defense mechanism (s) that afford protection against EBOV is not …

Abstract Background Ebola viruses (EBOVs) cause severe hemorrhagic fever with a high
mortality rate. At present, there are no licensed vaccines or efficient therapies to combat …

Ebola virus (EBOV) causes severe hemorrhagic fever for which there is no approved
treatment or preventive vaccine. Immunological correlates of protective immunity against …

Background: Persistent transmission of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, conceived in …

Ebola virus (EBOV) poses a significant threat to human health as highlighted by the recent
epidemic in West Africa. Data from animal studies and a ring vaccination clinical trial …

The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has
demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV …

Ebola virus (EBOV)-like particles (eVLP), composed of the EBOV glycoprotein and matrix
viral protein (VP) 40 with a lipid membrane, are a highly efficacious method of immunization …

Ebola virus (EBOV), isolate Makona, was the causative agent of the West African epidemic
devastating predominantly Guinea, Liberia and Sierra Leone from 2013–2016. While …